2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Clinical Guidelines, Practice Models, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Measurable Residual Disease, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult, Elderly
PAPER

3703 Real world outcomes of bispecific antibody (BsAb) therapy in rare aggressive large B-cell lymphoma (LBCL) patients (pts): A multicenter cohort study

Iliana Cosio, MD, Diana Abbott, PhD2, Jessica Allen, MD3, Devyn Coskey4, Aliya Rashid, DO, MPH5, Emma Williams, MD, PhD6, Himil Mahadevia, MBBS7, Kyle Austin Sugg, DO8, Dipenkumar Modi, MD9, Supreet Kaur10, Andrew Ip, MD, MS11, Madiha Iqbal, MBBS, MD12, Priyanka A. Pophali, MD13, Zachary A.K Frosch, MD14, Hua-Jay Jeffery Cherng, MD15, Narendranath Epperla, MD, MS, FACP16, Ajay Major, MD, MBA17, Cassandra Duarte, MD18
1 The University of Colorado, Aurora, Colorado, United States
2 The University of Colorado, Aurora, Colorado, United States
3 Huntsman Cancer Institute, Salt Lake City, Utah, United States
4 Columbia University Irving Cancer Research Center, New York, New York, United States
5 Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
6 University of Wisconsin-Madison, Madison, Wisconsin, United States
7 Mayo Clinic, Jacksonville, Florida, United States
8 Karmanos Cancer Institute, Detroit, Michigan, United States
9 Karmanos Cancer Institute, Detroit, Michigan, United States
10 Moffitt Cancer Center, Tampa, Florida, United States
11 Hackensack University Medical Center, Hackensack, New Jersey, United States
12 Mayo Clinic, Jacksonville, Florida, United States
13 University of Wisconsin-Madison, Madison, Wisconsin, United States
14 Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
15 Columbia University Irving Cancer Research Center, New York, New York, United States
16 Huntsman Cancer Institute, Salt Lake City, Utah, United States
17 The University of Colorado, Aurora, Colorado, United States
18 The University of Colorado, Aurora, Colorado, United States

Introduction: BsAb therapy with glofitamab (glofi), epcoritamab (epco), and mosunetuzumab (mosun) has transformed treatment of relapsed/refractory LBCL, but registrational trials excluded rare subtypes. Given the limited data on BsAb efficacy in rare LBCL subtypes, we conducted this study to evaluate real world outcomes associated with BsAb therapy. 

Methods: In this multicenter retrospective cohort study, pts with rare aggressive LBCL subtypes who received at least 1 dose of a BsAb alone or in combination were included. LBCL subtypes included: Burkitt Lymphoma (BL), HIV-associated LBCL, plasmablastic lymphoma (PBL), primary cutaneous diffuse LBCL, leg type, primary CNS lymphoma (PCNSL), post-transplant lymphoproliferative disorders (PTLD), Richter transformation (RT), secondary central nervous system lymphoma (SCNSL), and T-cell histiocyte rich LBCL (THRLBCL). Endpoints included response rates (overall response rate [ORR] and complete response rate [CRR]), overall survival (OS) and toxicity measures. 

Results: 61 pts were included: 14 SCNSL, 14 RT, 8 BL, 8 PTLD, 6 PBL, 6 THRLBCL, 2 PCNSL, 2 HIV-associated LBCL, and 1 primary cutaneous LBCL leg type. Median age was 63 years, 45 (74%) male, 49 (80%) White, and 8 (13%) Hispanic. Pts had a median of 3 prior lines of therapy before BsAB. Glofi was the most used agent (47.5%), then epco (32.8%); 56% had BsAb monotherapy. BsAb use was well tolerated with any grade cytokine release syndrome (CRS) rates of 32.8%, no G3+ CRS; 16.4% immune effector cell-associated neurotoxicity syndrome (ICANS), 5% grade 3+. Of note, in PCNSL no CRS or ICANS was reported; in SCNSL 50% had any grade CRS, 7% G3+, 29% had any grade ICANS, 7% G3+. 21% of pts had infectious complications. Of those with infections, 13% were viral. 79% of pts had no treatment related infection. 

With a median f/u time of 8.2 months (mo), cohort OS was not reached (NR), with ORR 44%, CRR 33%. Detailed breakdown provided below for BL, PTLD, and PBL. Additional data such as progression free survival and data on other subtypes including PCNSL, SCNSL, and RT will be presented at ASH Conference. 

BL (N=8): 88% had BL-International Prognostic Index (IPI) high risk. 25% had prior autologous transplant (ASCT), 38% with prior CAR T and 25% with prior allotransplant (allo). 75% had glofi with 1 pt each receiving epco or mosun. Median OS was 10.8mo with 50% CRR and 63% ORR. CRS occurred in 38% of pts with no ICANS.  

PTLD (N=8): 75% of pts had IPI score of 3-5. All pts had monomorphic PTLD (3 DLBCL, 2 BL and 2 other). 1 pt had multiple organs transplanted (liver, pancreas, small bowel); 6 pts had single organ transplant (2-heart, 1-lung, 1-liver, 2-kidney). Two pts were EBER positive. 50% of pts had prior CAR T with no pts receiving ASCT or allo. 62.5% of pts had glofi while 12.5% of pts each received epco, mosun or other with 75% of pts receiving BsAb combination therapy. Median OS was 10.5mo with 38% CRR and 38% ORR. Rates of any grade CRS, ICANS, and treatment related infection were 38%, 25% and 38% respectively.  

PBL (N=6): 50% of pts had IPI score of 3-5, 50% were EBER positive and 33% were HIV positive. 1 pt had prior ASCT and 1 pt had prior CAR T (BCMA). 67% of pts received teclistamab, with 16% receiving elranatamab and talquetamab each. 83% received BsAb monotherapy. Median OS was NR. CRR was 33% with ORR 33%. No pts had CRS, 33% had ICANS, 50% had infectious complications.  

Discussion: This analysis represents the largest reported cohort of pts with BL and PBL treated with BsAb. Outcomes for BL pts remain poor, with a median OS of < 1 year. In contrast, OS was NR in PBL pts, and several pts treated with BCMA-directed BsAb achieved durable responses. For PTLD, our findings add to the growing body of evidence supporting the use of BsAb in this population. In a prior study of 10 PTLD pts (Dave Blood 2025) treated with BsAb ORR was 60%, compared with 38% in our cohort. In contrast, both the ORR and rates of treatment-related complications were lower in our cohort. The reasons for these differences could be variations in patient characteristics, disease burden or prior therapies. The results of ongoing prospective studies are anticipated to further clarify the efficacy and safety of BsAb in these rare lymphoma subtypes.

Iliana Cosio, MD: No relevant conflicts of interest to declare.